The overlap or collision between drug patent law and the right to confidentiality and the exclusive use of clinical testing data
DOI:
10.16928/2316-8080.v7n1p.135-155Keywords:
Overlapping rights Intellectual property Patents Clinical test data Public policiesAbstract
The overlapping of intellectual property rights is a question common to all the institutions protected by these rights and is the object of studies and discussions in Brazil and abroad, still without a solution or alternatives for reconciliation. Particularly in the field of pharmaceutical patents, it is pertinent to analyse the deleterious consequences for public policies on access to medicines when the patent system is frustrated by the right to confidentiality and to the exclusive use of clinical trial data.
References
BARBOSA, Denis Borges. Uma introdução à propriedade intelectual, v. I e III. Rio de Janeiro: Lumens Juris, 2010.
BARBOSA. Do sigilo dos testes para registro sanitário, 2009. Disponível em: grotius.net/arquivos/200/propriedade/93.doc. Acesso em 25/11/2013. DOI: https://doi.org/10.15600/1679-5350/rau.v11n3p25-48
BARBOSA. Uma introdução à propriedade intelectual. Rio de Janeiro: Lumens Juris, 2003.
BARBOSA, Pedro Marcos Nunes. A proteção dos dados de testes sigilos submetidos à regulação estatal. Disponível em: http://www.nbb.com.br/pub/propriedade07.pdf. Acesso em: 25/11/2013.
CORIAT, Benjamin; ORSI, Fabienne & D`ALMEIDA, Cristina. TRIPS and the international public health controversies: issues and challenges. In Industrial and Corporate Change, novembro, 2007, p. 07.
CRUQUENAIRE, Alexandre & DUSOLLIER Séverine. Le cumul des droits intellectuels. Bélgica: Larcier, 2004.
CURLEY, Duncan & HORST, Marleen. Patents and regulatory data exclusivity for medicinal products. In WILKOF, Neil & BASHEER, Shamnad. Overlapping Intellectual Property Rights. London: Oxford, 2012, p. 119-136. DERCLAYE Estelle & LEISTNER Matthias. Intellectual Property Overlaps - A European Perspective. Oregon: Hart Publishng, 2011.
DIAS, Cláudia Regina Cilento; ROMANO-LIEBER, Nicolina Silvana. Processo da implantação da política de medicamentos genéricos no Brasil. Cad. Saúde Pública, Rio de Janeiro, v. 22, n. 8, Agosto de2006. Disponível em http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102311X20060008000 14&lng=en&nrm=iso. Acesso em 30/11/2013. DOI: https://doi.org/10.1590/S0102-311X2006000800014
GORDON, Wendy. Fair Use as Market Failure: A Structural and Economic Analysis of the Betamax Case and Its Predecessors, Columbia Law Reviw. n. 82, 1982. DOI: https://doi.org/10.2307/1122296
HASENCLEVER, Lia. O Mercado de Medicamentos Genéricos no Brasil. Disponível em http://www.patentes.org.br/media/file/Patentes/hasenclever_ufrj_%20mercado_m edicamentos_genericos.PDF. Acesso em 30/11/2013.
LANDES, William & Richard Posner. The Economic Structure of Intellectual Proprety Law. Cambridge: Belknap Press, 2003. DOI: https://doi.org/10.4159/9780674039919
LIPSZYC, Delia. Derecho de autor e derechos conexos. Buenos Aires: Zavalia, 1993.
MOFFAT, Viva. Mutant Copyrights and Backdoor Patents: Theproblem of overlapping intellectual property protection. Berkeley Technology Law Journal, vol. 19, 2004; U Denver Legal StudiesResearch Paper Series. Disponível em: http://ssrn.com/abstract=972358. Acesso em 10/01/2009.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain copyright in their work and grant the journal the right of first publication. The licence applicable to this article is the one stated on its own page and corresponds to the policy in force on its date of publication.
Authors are permitted to deposit the published version in institutional and subject repositories, provided the original publication in this journal is acknowledged.
PIDCC charges no submission, processing or publication fees.
